Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients

Conev, Nikolay; Donev, Ivan; Konsoulova, Assia; Chervenkov, Trifon; Kashlov, Yavor; Ivanov, Krasimir

doi:10.5582/bst.2015.01170

Cited by 36 publications

(31 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In colorectal cancer, Expression of miR-17, miR-21 and miR-92 were significantly higher in serum of patients with disease relapse. Thus serum miR-21, miR-17, and miR-92 expression in colorectal cancer patients who underwent radical surgery and adjuvant chemotherapy may have diagnostic value in the differentiation between recurred and non-recurred patients [39]. …”

Section: Discussionmentioning

confidence: 99%

The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Purpose: Intestinal metaplasia is considered to be a pre-cancerous lesion of gastric cancer. The miR-17-92 cluster was previously reported to have clinical value in the prediction of cancer development. This study aimed to test the diagnostic value of miR-17-92 in gastric cancer and the intestinal metaplasia patients compared with the normal ones.Results: The results showed that miR-17-92 members were over-expressed in the serum of both gastric cancer and intestinal metaplasia patients, compared with healthy controls. Serum miR-17-92 members could also distinguish patients with gastric cancer and intestinal metaplasia from healthy controls. Materials and Methods: Serum miR-17-92 expression levels were detected using quantitative real-time PCR in 75 patients with gastric cancer, 104 patients with intestinal metaplasia and 38 healthy controls. The Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were then analyzed to test the efficacy of the miR-17-92 members in distinguishing gastric cancer, intestinal metaplasia and healthy controls.Conclusions: In conclusion, the miR-17-92 cluster might be useful as a potential serum biomarker for the early detection of gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Serum miRNA-365 expression correlates with overall survival of patients with non-small cell lung cancer [15]. Serum expression levels of miRNA-17, miRNA-21, and miRNA-92 predict recurrence after adjuvant chemotherapy in colon cancer patients [16]. Serum miRNA-183 can be used to predict the response of renal cell carcinoma cells to the cytotoxicity induced by natural killer cells [17].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer

Hou

Luo

2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Aims: Recent studies have demonstrated that microRNAs (miRNAs) can serve as useful biomarkers for human cancers. The aim of this study was to evaluate the expression level of serum miRNA-206 in patients with gastric cancer (GC) and investigate its diagnostic and prognostic value. Methods: Quantitative real-time PCR was performed to evaluate serum miRNA-206 levels in 150 GC patients and 150 healthy volunteers. The association between miRNA-206 expression and clinicopathological factors as well as patient's survival was analyzed. Receiver operator curve (ROC) analysis was carried out to assess the potential value of serum miRNA-206 for GC diagnosis. Results: Serum miRNA-206 was down-regulated in GC patients compared with healthy controls (P < 0.001). Decreased serum miRNA-206 expression was significantly associated with deep local invasion, positive lymph node metastasis, and advanced clinical stage. Serum miRNA-206 expression was found to be significantly up-regulated in paired post-operative samples and reduced in patients with GC recurrence. ROC curve analysis showed that serum miRNA-206 was a useful marker for GC diagnosis, and could discriminate between recurred and non-recurred patients. Multivariate Cox regression analysis confirmed low serum miRNA-206 expression as an independent unfavorable prognostic factor for both DFS and OS of GC patients. Conclusions: These results suggest that serum miRNA-206 might not only serve as a novel diagnostic biomarker for GC, but also predict cancer recurrence and patient's prognosis.

show abstract

“…One study evaluated the diagnostic role of miR-29a and the related combination markers in the recurrence of CRC. In the study, miR-29a could discriminate recurred patients from non-recurred stage III CRC patients with a sensitivity of 50.0%, a specificity of 42.9% and the AUC of 0.452 while the combination markers (miR-29a, miR-92, miR-17 and miR-21) increased the diagnostic power for the patients, yielding an AUC of 0.881, with a sensitivity of 83.3% and a specificity of 85.7% (P < 0.05) [41]. In another study, the sensitivity of miR-29a for identifying recurrence in CRC was 31.0%, the specificity was 98.0% [42].…”

Section: Recurrence Prediction Value Of Mir-29 and The Combination Mamentioning

confidence: 96%

“…After manually screening the titles, abstracts and keywords and then checking the full texts, 9 articles involving 10 studies for individual miR-29 and 5 articles containing 6 studies for miRNA combination markers based on miR-29 that met the inclusion norm were finally selected for the diagnostic meta-analysis while six publications including eight studies evaluating the survival outcome were identified eligible in the prognostic meta-analysis [27][28][29][30][31][32][33][34][35][36][37][38][39]. Moreover, three studies assessed the roles of miR-29 and miRNA combination markers in the recurrence prediction of CRC and one study evaluated the biomarker role in the metastasis prediction in CRC [40][41][42][43]. The characteristics of the eligible studies were summarized in Tables 1, 2 and 3.…”

Section: Study Identification and Characteristics Of Included Studiesmentioning

confidence: 99%

Integrated analyses of microRNA-29 family and the related combination biomarkers demonstrate their widespread influence on risk, recurrence, metastasis and survival outcome in colorectal cancer

et al. 2019

View full text Add to dashboard Cite

Background Emerging evidence has revealed miR-29 family as promising biomarkers for colorectal cancer (CRC), but their biomarker potential and molecular mechanisms remain poorly understood. Methods We performed a comprehensive meta-analysis to evaluate the biomarker performance of individual miR-29 and the related miRNA combination biomarkers. Meanwhile, we conducted an integrative bioinformatics analysis to unfold the underlying biological function of miR-29 and their relationship with CRC. Results Using miR-29 expression to diagnose CRC produced 0.82 area under the curve, 70% sensitivity and 81% specificity while the combination biomarkers based on miR-29 enhanced the diagnostic power with an AUC of 0.86, a sensitivity of 78% and a specificity of 91%. For the prognosis evaluation, patients with higher expression of miR-29 had better survival outcome (pooled HR 0.78; 95% CI 0.56–1.07). In addition, miR-29 has also been identified as potential biomarker for predicting recurrence and metastasis in CRC. Then the genes regulated by the miR-29 family were retrieved and found closely associated with the molecular pathogenesis of CRC according to the gene ontology and pathway analysis. Furthermore, hub nodes and significant modules were identified from the protein–protein interaction network constructed with miR-29 family targets, which were also confirmed highly involved in the establishment and development of CRC. Conclusions Current evidences suggest miR-29 family may become promising biomarkers for risk, recurrence, metastasis and survival outcome of CRC. Meanwhile our data highlight the potential clinical use of miRNA combination biomarkers. Nevertheless, further prospective studies are warranted before the application of the useful biomarkers in the clinical.

show abstract

Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients

Cited by 36 publications

References 37 publications

The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review

The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review

Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer

Integrated analyses of microRNA-29 family and the related combination biomarkers demonstrate their widespread influence on risk, recurrence, metastasis and survival outcome in colorectal cancer

Contact Info

Product

Resources

About